Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib +/- chemo/bevacizumab in EGFR+ NSCLC with uncleared ctDNA
NCT05334277Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of furmonertinib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 34 months. Started May 2022; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05334277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05334277.